In a landmark development for medical data collaboration and pharmaceutical innovation, Beijing Tongren Hospital, a leading Chinese medical institution specializing in ophthalmology, has announced the completion of the world’s first legally compliant transaction of a full-dimensional ophthalmic follow-up dataset, with agreements signed with two major drugmakers: China’s Hengrui Pharmaceuticals and German multinational Bayer.
Hospital president Yuan Jin detailed that the sold dataset is drawn from the facility’s comprehensive multi-dimensional, fully structured quantitative ophthalmic database, which has been constructed around anonymized health records from a 100,000-strong patient population. The dataset covers full-cycle clinical follow-up information for all common high-prevalence eye diseases, including keratopathy, dry eye syndrome, myopia, glaucoma, cataracts, and diabetic retinopathy.
Unlike fragmented medical data collections, this integrated dataset combines multiple layers of clinically valuable information: patient demographic characteristics, confirmed clinical diagnoses, adopted treatment plans, long-term post-treatment follow-up records, and standardized ophthalmic imaging results. This rich, multi-faceted real-world data is expected to fill critical gaps in ophthalmic drug development, supporting not only early-stage new drug research but also post-marketing efficacy evaluations, medical insurance access assessments, and the training of clinical artificial intelligence tools focused on eye health.
To address growing global concerns around medical data privacy and regulatory compliance, the transaction was conducted through two established, authoritative Chinese platforms: the National AI Application Pilot Base for the Medical Sector and the Beijing International Big Data Exchange. Prior to the transaction, all sensitive personal identifiable information was fully removed and anonymized, aligning with China’s strict personal health information protection regulations and eliminating privacy risks for former patients.
Beijing Tongren Hospital emphasized that the core goal of this pioneering transaction is to advance ophthalmic medical research and ultimately improve treatment outcomes for patients living with eye diseases around the world. This milestone is widely expected to set a regulatory and operational precedent for future compliant medical data transactions that balance innovation, public health benefit, and patient privacy protection.